Edward W. Unkart - 11 Jun 2026 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: Director
Issuer ticker: KALV
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:29:02 UTC
Prior SEC filing: 02 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Edward W. Unkart filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 11 Jun 2026.

Key facts

This page summarizes Edward W. Unkart's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 16:29.

Change

Previous filing in this sequence was filed on 02 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001306267 Primary reporting owner

Unkart Edward W

Relationship: Director
Address: C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -12,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $7.88
Footnotes: F1, F2, F3

KALV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -6,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $6.71
Footnotes: F1, F2, F3

KALV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $17.45
Footnotes: F1, F2, F3

KALV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,000
Exercise price: $22.65
Footnotes: F1, F2, F3

KALV transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -30,000
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $12.05
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Edward W. Unkart is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").

Footnote F2

The option is fully vested.

Footnote F3

Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.

Footnote F4

The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.